An observational study in Head and Neck Cancer (H&N) and Thyroid Cancer, sponsored by Aarhus University Hospital. Enrolling by invitation at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Aarhus University Hospital · Observational
The overall aim is to investigate whether genetic and other molecular markers can improve the diagnosis, assessment of treatment response, and detection of recurrence in patients with head and neck cancer. In the longer term, the project aims to contribute to more individualised treatment strategies for our patients.
The project will involve comprehensive analyses of tumour tissue and blood, including extensive genetic sequencing and other molecular profiling. Importantly, the research analyses will not have any implications for the clinical management or treatment of the individual patient included in the study.
785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 178 across 241 observational studies indexed under Thyroid Neoplasms.
Browse Thyroid Neoplasms studies →Aarhus University Hospital is the lead sponsor of 298 studies on the registry; 80 are open to participants now.
Compared within Thyroid Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients suspected of Head and neck cancer or thyroid cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Number of somatic variants in head- and neck cancer based on DNA sequencing data
WGS on tumor tissue
Time frame: At study inclusion (pretreatment)
Number of RNA alterations in head- and neck cancer based on RNA sequencing data
Total RNA sequencing in tumor tissue
Time frame: At study inclusion (pretreatment)
Prevalence of ctDNA in blood in head- and neck cancer patients before and after treatment
WGS
Time frame: At study inclusion (pretreatment), and during follow-up: 2, 6, 12, 18, 24 months after treatment
The prevalence of microbioma in tumor tissue of head and neck cancer
Sequencing analysis of bacterial DNA
Time frame: At study inclusion (pretreatment)
Growth of tumormodels from head and neck cancer
Tumormodels from tumor samples from head and neck cancer patient
Time frame: At study inclusion (pretreatment)
Microbioma in saliva
Sequencing analysis of bacterial DNA
Time frame: At study inclusion (pretreatment), and 2 months after treatment during follow-up
Prohibition of growth of tumormodels from head and neck cancer due to phamacological inhibition: size of tumor
Tumormodels from tumor samples from head and neck cancer patient
Time frame: At study inclusion (pretreatment)
Plan to share: Undecided — Due to patient confidentiality and compliance with Danish legislation
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Jul 2033, 81 months after the start.
Of 103 non-industry observational studies under Thyroid Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 311. This study's planned 81 months is above that.
Counting every sponsor, half of 112 studies reached it within 63 months; a quarter within 26 and three quarters within 311.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.